Literature DB >> 22340562

Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.

Li Yang1, Wei Zhao, Wen-Shu Zuo, Ling Wei, Xian-Rang Song, Xing-Wu Wang, Gang Zheng, Mei-Zhu Zheng.   

Abstract

BACKGROUND: Osteopontin (OPN) is a secreted phosphoglycoprotein (SSP) that is overexpressed in a variety of tumors and was regarded as a molecular marker of tumors. In this study, we intended to demonstrate the role of OPN in human breast cancer cell line MDA-MB-231.
METHODS: Recombinant plasmid expressing small interfering RNA (siRNA) specific to OPN mRNA was transfected into MDA-MB-231 cells to generate the stable transfected cell line MDA-MB-343, and the empty plasmid tansfected cells (MDA-MB-neg) or wildtype MDA-MB-231 cells were used as control cells respectively. Expression of OPN, hypoxia inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) proteins was analyzed by Western blotting analysis. The radiosensitivity of cells was determined by detecting cell apoptosis, cell proliferation and cell senescence.
RESULTS: HIF-1 and VEGF proteins in MDA-MB-343 cells were significantly downregulated upon the efficient knockdown of OPN expression under either hypoxia or normoxia environment. Moreover, expression of OPN protein was upregualted upon hypoxic culture. Stable OPN-silencing also decreased cell invasion, increased cell apoptosis and cell senescence, as well as reduced clonogenic survival, resulting in increase radiation tolerance.
CONCLUSIONS: Suppression of OPN gene expression can enhance radiosensitivity and affect cell apoptosis in breast cancer cells. OPN seems to be an attractive target for the improvement of radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340562

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  9 in total

1.  The downregulation of OPN inhibits proliferation and migration and regulate activation of Erk1/2 in ECA-109 cells.

Authors:  Song-Tao Xu; Fa-Zhang Zou; Li-Na Cai; Wan-Ling Xu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma.

Authors:  Xinqiong Huang; Yujie Qian; Hainan Wu; Xiaoxue Xie; Qin Zhou; Ying Wang; Weilu Kuang; Lin Shen; Kai Li; Juan Su; Liangfang Shen; Xiang Chen
Journal:  J Histochem Cytochem       Date:  2014-11-07       Impact factor: 2.479

3.  Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma.

Authors:  Xin Li; Xinyu Su; Chen Yan; Yuanyuan Ma; Heng Li; Jianhong Xia; Hongliang Li; Qian Jiang; Liqing Zhou; Zhengyun Zou
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-29       Impact factor: 4.553

4.  Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.

Authors:  M A Elbaiomy; T Akl; R Elhelaly; W El-Beshbishi; M S El Ghonemy; R Elzehery
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

5.  Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling.

Authors:  Yanlan Chai; Juan Wang; Ying Gao; Tao Wang; Fan Shi; Jin Su; Yunyi Yang; Xi Zhou; Liping Song; Zi Liu
Journal:  J Radiat Res       Date:  2014-09-24       Impact factor: 2.724

6.  Osteopontin splice variants are differential predictors of breast cancer treatment responses.

Authors:  Krzysztof Zduniak; Anil Agrawal; Siddarth Agrawal; Md Monir Hossain; Piotr Ziolkowski; Georg F Weber
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

Review 7.  Osteopontin -- a promising biomarker for cancer therapy.

Authors:  Ran Wei; Janet Pik Ching Wong; Hang Fai Kwok
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

Review 8.  The role of osteopontin in the progression of solid organ tumour.

Authors:  Hailin Zhao; Qian Chen; Azeem Alam; Jiang Cui; Ka Chun Suen; Aurelie Pac Soo; Shiori Eguchi; Jianteng Gu; Daqing Ma
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

Review 9.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.